Imatinib

證據等級: L5

預測適應症: 10 個

Two structural notes before the report: (1) per template, "Predicted New Indication" must be taken from predicted_indications[0], which here is heart fibrosarcoma (L4, Hold) — not the much better-evidenced rank-2 candidate (fibroblastic neoplasm/DFSP, L2). I flag that discrepancy inline since it matters for interpretation. (2) original_indications and taiwan_regulatory.licenses are both empty in this pack, so the "Original Indication" cell uses imatinib's well-established public-record indications (CML/GIST), explicitly labeled as such rather than sourced from this evidence pack.

Imatinib: From Chronic Myeloid Leukaemia to Heart Fibrosarcoma

One-Sentence Summary

Imatinib is a tyrosine kinase inhibitor originally developed for chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours (GIST). The TxGNN model's top-ranked prediction for this drug is Heart Fibrosarcoma, but this specific candidate is currently supported by only 1 publication and no clinical trials — evidence is essentially model-only.

Quick Overview

Item	Content
Original Indication	Chronic myeloid leukaemia (CML) / GIST (general knowledge — not sourced from this evidence pack; no Fimea label text available)
Predicted New Indication	Heart Fibrosarcoma
TxGNN Prediction Score	99.94% (rank 952)
Evidence Level	L4
Finland Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in this evidence pack (MOA marked as a data gap). Based on general knowledge, imatinib is a small-molecule tyrosine kinase inhibitor targeting BCR-ABL, KIT, and PDGFR/PDGFRB — a mechanism well-proven in CML and GIST, and mechanistically it may extend to tumours driven by PDGFRB fusion signalling.

However, the specific link to heart fibrosarcoma is weak. Per the evidence pack's own rationale: "There is a theoretical extension to the PDGFRB-fusion-driven fibrosarcoma family, but primary cardiac fibrosarcoma is extremely rare, and no organ-specific mechanistic data support this link." No tumour-genotyping data confirms PDGFRB involvement in this specific, ultra-rare cardiac tumour subtype.

Notably, other TxGNN-predicted candidates in the same fibrosarcoma/fibroblastic-neoplasm family show substantially stronger evidence — in particular "fibroblastic neoplasm" (rank 2, corresponding largely to dermatofibrosarcoma protuberans), where the COL1A1-PDGFB fusion is a textbook imatinib target with L2 evidence and a "Proceed with Guardrails" recommendation. This lends indirect, class-level plausibility to the PDGFR-driven mechanism, but does not substitute for direct evidence in heart fibrosarcoma specifically.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
18623899	2008	Commentary	Prescrire international	Reviews imatinib's gradually expanding indications beyond CML/GIST (e.g., Ph+ ALL); concludes evidence for newer indications is "not robust." Does not address cardiac fibrosarcoma specifically.

Finland Market Information

Imatinib currently has no marketing authorization records in Finland in this dataset (market status: not marketed; 0 authorizations).

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (tyrosine kinase inhibitor; not a conventional cytotoxic agent)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is high, but for this specific indication (heart fibrosarcoma) there is only one non-specific commentary article and zero clinical trials. Primary cardiac fibrosarcoma is exceedingly rare, and no organ- or tumour-specific mechanistic data (e.g., PDGFRB fusion status) supports the link — this is currently a model-prediction-only signal (consistent with the pack's own L4/Hold scoring).

To proceed, the following is needed:

TFDA/Fimea package insert data (currently blocking — DG001)
Detailed mechanism-of-action confirmation (currently a high-severity gap — DG002)
Case reports or preclinical data confirming PDGFR/KIT/BCR-ABL pathway activity specifically in cardiac fibrosarcoma
Consider re-evaluating the higher-evidence candidate in this same prediction set ("fibroblastic neoplasm"/DFSP, L2, Proceed with Guardrails) as a more actionable near-term repurposing target
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.